THE SIDE EFFECTS OF CHEMOTHERAPY IN GLIOMA
Keywords:
Chemobrain, chemotherapy, CIPNP, gliomaAbstract
The increasing number of people who survive in the long term because of the advanced of glioma therapy with chemotherapy causes more slowly emerging neurologic side effects. Currently, there were three medical treatments are approved by the FDA for the management of glioblastoma namely temozolomide, carmustine wafer, and bevacizumab. However, most of the traditional chemotherapy drugs have a target in cell proliferation and cause toxicity of healthy cells. The side effects of chemotherapy on central nervous systems are chemobrain, acute encephalopathy, leukoencephalopathy, cerebellar dysfunction, and spinal cord toxicity. In addition, severe chemotherapy side effects may also occur in the peripheral nervous system called Chemotherapyinduced peripheral neuropathic pain (CIPNP). The clinician should recognize the symptoms of those side effect in glioma patients who received chemotherapy.
References
Lapointe, S, Perry A, Butowski NA. Primary brain tumours in adults. The Lancet; 2018.392(10145),432–446. DOI: 10.1016/s0140-6736 (18)30990-5
Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches; 2011.12(September):495–508. DOI: 10.1038/nrn3060
Rees JH, Wen PY. Blue books of neurology. philadelphia: Elsevier; 2010.p. 352-371
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: A state of the science review. Neuro Oncol; 2014.16(7):896–913. DOI: 10.1093/neuonc/nou087
Parisi S, Corsa P, Raguso A, Perrone A, Cossa S, Munafò T, et al. Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. BioMed Research International; 2015.1–7. DOI: 10.1155/2015/620643
Simó M, Rifà -ros X, Rodriguez-fornells A, Bruna J. Chemobrain: A systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev; 2013.1–11. DOI: http://dx.doi.org/10.1016/j.neubiorev.2013.04.015
Michaud K, Chang SM. Principles of chemotherapy in youmans neurological surgery. in: sixth edit. Saunders; 2011. p. 1236–42
Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). Am J Neuroradiol; 2010.31(8):1383–4. DOI: 10.3174/ajnr.A2170
Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer; 2007.7(3):192–201. DOI: 10.1038/nrc2073
Abrey LE. The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors. 2012.285–90. DOI: 10.1007/s11060-012-0807-6
Ahles TA, Root JC, Ryan EL. Journal of clinical oncology cancer and cancer treatment – associated cognit ive change : an update on the state of the science; 2015.30(30). DOI: 10.1200/JCO.2012.43.0116
Schagen SB, Wefel JS. Chemotherapy-related changes in cognitive functioning. Ejc Suppl; 2016.11(2):225–32. DOI: http://dx.doi.org/10.1016/j.ejcsup.2013.07.007
Nokia MS, Anderson ML, Shors TJ. Chemotherapy disrupts learning, neurogenesis and theta activity in the adult brain; 2012.36(May):3521–30. DOI: 10.1111/ejn.12007
Sindhwani G, Arora M, Thakker VD, Jain A. MRI in chemotherapy induced leukoencephalopathy: report of two cases and radiologist’s perspective. J Clin Diagn Res; 2017.11(7): TD08-TD09. DOI: 10.7860/JCDR/2017/29164.10248
Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol; 2014.10(12):694–707. DOI: 10.1038/nrneurol.2014.211
Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends in Cell Biology; 2013. 23(12), 612–619. DOI: 10.1016/j.tcb.2013.08.003
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol/Hematol; 2012.82(1):51–77. DOI: http://dx.doi.org/10.1016/j.critrevonc.2011.04.012
Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag; 2014.6, 135–147 DOI: 10.2147/CMAR.S44261
